Reaching and educating underserved patient populations in a compliant and impactful way is no small feat. In Q1 2024, Underscore Marketing set a new benchmark with an unbranded campaign for patients with a rare lung disease. By leveraging PulsePoint’s Qualified Audience Reach (QAR) metric and collaborating with Symphony Health, the campaign identified and reached patients efficiently and compliantly. Symphony Health stood out, achieving a cumulative QAR score of 2.3 and reaching over 100 qualified patients in just three days—half the time it took other providers. Read our latest case study to find out how: https://ow.ly/sAxN50Usp3F #HealthcareMarketing #DataDriven #PatientCentricCare
Sobre nosotros
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
- Sitio web
-
http://www.iconplc.com
Enlace externo para ICON plc
- Sector
- Investigación biotecnológica
- Tamaño de la empresa
- Más de 10.001 empleados
- Sede
- Dublin
- Tipo
- Empresa pública
- Especialidades
- Medical Device, Therapeutics, Government and Public Health Solutions, Clinical Research Services, Commercialisation and Outcomes, Oncology, Value Based Healthcare, Clinical Trials, Patient Recruitment, Innovation, Regulatory Affairs, Strategic Consulting, Medical Affairs y Global Patient Insights & Engagement
Ubicaciones
Empleados en ICON plc
Actualizaciones
-
Barry Balfe, ICON Pharma Solutions President, featured in The Irish Times discussing the pivotal role of life sciences in Ireland's economic success and the steps needed to secure the country’s competitive edge. Barry highlights Ireland’s strong foundation in biopharma, medtech, and life sciences R&D, emphasising the importance of public investment in research, adapting to revolutions in AI and biomedical science, and addressing key challenges like infrastructure and clinical trial regulations. Read the full article here: https://ow.ly/aJfH50UtY0F #LifeSciences #R&D #Ireland #Leadership #ICONPharma
-
-
Signal detection, global regulatory compliance, and advanced technologies in pharmacovigilance: just some of the topics covered at 2024 World Drug Safety Congress recently. ICON experts attended and report on the discussions and emerging trends in this blog. Read the article. https://ow.ly/GNJH50UqwKt
-
-
Simplifying clinical supplies management with FlexAdvantage just got easier. The newest enhancements to FlexAdvantage streamline your clinical supply chain with: - Intuitive navigation with seamless access - Shipment acknowledgment reminders - Automated temperature excursion tracking for compliance - End-to-end efficiency to keep your trial on track Learn how FlexAdvantage transforms your clinical supply chain: https://ow.ly/CFW450UuNkI
-
We demystify the systematic literature review (SLR) process by providing an overview of the steps involved in conducting an SLR, when to conduct an SLR, and how SLRs contribute to evidence-based medicine and improve patient outcomes. View the on demand webinar: https://ow.ly/rkSs50UqrqG
-
-
How is AI shaping the future of drug development? Tom O’Leary, ICON’s Chief Information Officer, discusses with The Irish Times how AI is revolutionising the industry. From accelerating drug discovery to streamlining clinical trials, AI is optimising processes, enabling data-driven decisions, and delivering patient-centred innovations. ICON’s cutting-edge platforms, such as OneSearch and Cassandra, exemplify how technology is transforming site selection, patient recruitment, and regulatory planning. Click here to learn more in The Irish Times: https://ow.ly/M4N250UtXUw #ClinicalResearch #ArtificialIntelligence #InnovationInHealth
-
-
Patient-centered research is no longer optional—it is essential. With increasing pressure on pharmaceutical sponsors to demonstrate the real-world impact of treatments, leveraging the right mix of COAs and digital health tools is key to selecting measures that truly matter to patients. Read more here: https://ow.ly/9rr650UoSs7 #ClinicalOutcomeAssessments #PatientCentricity #ClinicalTrials
-
-
ICON plc ha compartido esto
Curious about the latest trends shaping the future of oncology? Unlock key biotech insights on oncology R&D trends: https://ow.ly/Vp6F50Uu8C8 with ICON plc Biotech. Access this short video to explore the key therapeutic approaches in development, the biggest challenges in clinical trials, where AI/ML is making the biggest impact, and a future outlook on the trends driving innovation. Access it here: https://ow.ly/Vp6F50Uu8C8.
-
-
At ICON, we're committed to breaking barriers and building opportunities for women in STEM. Rose Kidd, President of Operations Delivery, was recently featured in The Irish Times, where she highlighted our efforts to achieve gender parity at leadership levels and inspire young women to pursue rewarding careers in STEM and life sciences. Read more about how we’re making progress and why continued focus and investment is so important: https://ow.ly/lXPZ50UtXHP #STEMLeadership #DiversityInSTEM #LifeSciences
-
-
ICON experts discuss the prevalence of metabolic-dysfunction associated steatotic liver disease (MASLD) in obese patients and the significance of weight loss in managing hepatic complications. Read the blog. https://ow.ly/43sl50UoV1u #ObesityResearch #LiverHealth
-
Páginas asociadas
Páginas similares
Financiación
ICON plc
1 ronda en total
Ver más información en Crunchbase
Última ronda
Deuda tras OPV
Enlace externo a Crunchbase para la última ronda de financiación
2.000.000.000,00 US$